News
Results from the Phase III ATTAIN-1 trial (NCT05869903) showed that the highest dose of orforglipron achieved an average ...
In the Phase III TRIUMpH program, tegoprazan met primary endpoints and outperformed lansoprazole in maintaining healing of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback